ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2018.5801 ETM-0-0-5801 Articles Association between HLA gene polymorphism and cutaneous adverse reactions caused by antiepileptic drugs ZhangJingang 1 2 * LiXinrui 1 * SuYuanyuan 1 SunMin 3 WangJunbang 4 HaoYunhua 1 Department of Neurology, Tianyou Hospital, Tongji University, Shanghai 200331, P.R. China Department of Neurology, Dahua Hospital, Shanghai 200331, P.R. China Department of Cardiology, Shandong Energy Zaozhuang Mining Group Central Hospital, Zaozhuang, Shandong 277800, P.R. China Translational Stem Cell Research Center, Tongji Hospital, Tongji University School of Medicine, Shanghai 200331, P.R. China Correspondence to: Dr Yunhua Hao, Department of Neurology, Tianyou Hospital, Tongji University, 528 Zhennan Road, Putuo, Shanghai 200331, P.R. China, E-mail: yunhua_hao@163.com

Contributed equally

 04 2018 25 01 2018 15 4 3399 3403 16082017 15012018 Copyright: © Zhang et al. 2018 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The association between cutaneous adverse drug reactions (cADRs) caused by antiepileptic drugs (AEDs) and human leukocyte antigen-A (HLA-A) and HLA-B genes in Chinese Han population in Shanghai was investigated. Through the case-control study, 30 child patients with AED-induced cADRs (cADRs group), 60 AED-tolerant child patients (AED-tolerant group) and 60 normal children not taking AEDs (normal group) were collected. The HLA-B*15:02 and HLA-A*31:01 genotypes were detected using the polymerase chain reaction-sequence-specific oligonucleotide (PCR-SSO) probe method, and the correlation of HLA-B*15:02 and HLA-A*31:01 genes with the incidence of cADRs was analyzed. The positive rate of HLA-B*15:02 gene was 83.33% in the cADRs group, which was significantly increased compared with that in the AED-tolerant and normal groups (P<0.01). The positive rate of HLA-A*31:01 gene was 63.33% in the cADRs group, which was obviously increased compared with that in the AED-tolerant and normal groups (P<0.01). There were no significant differences in HLA-B*15:02 and HLA-A*31:01 genotypes between the AED-tolerant and normal groups (P>0.05). The results showed that HLA-B*15:02 and HLA-A*31:01 are significantly associated with cADRs in a Chinese Han population in Shanghai, suggesting that HLA-B*15:02 and HLA-A*31:01 genotypes should be detected in the application of AEDs.

 antiepileptic drugs cutaneous adverse reactions HLA-B*15:02 HLA-A*31:01 Introduction

Epilepsy (EP) is a common neurological disease caused by abnormal brain cell super-synchronous discharge with the main clinical features of repeated attack, transiency and stereotype (1), which occurs more frequently in children. There are approximately 10 million patients with epilepsy currently in China, and its incidence rate increases year by year with an annual increase of 450,000 individuals, seriously affecting the lives of patients (2).

At present, commonly used antiepileptic drugs (AEDs) in clinical practice include carbamazepine, phenytoin sodium, phenobarbital, lamotrigine, primidone and oxcarbazepine (3). There is a large difference in the blood concentration of AEDs in individuals, and adverse drug reactions often occur easily, the most common of which is the cutaneous adverse drug reaction (cADR) (4). The clinical manifestations of cADRs are maculopapule (MPE), Stevens-Johnson syndrome (SJS), drug hypersensitivity syndrome (HSS) and toxic epidermal necrolysis (TEN) (5,6) The incidence rates of SJS/TEN are lower (1:10000-6:10000 in European countries and 1:1000-6:1000 in Asian countries), but their fatality rates are extremely high (7), thus greatly limiting the clinical application of AEDs (8). In recent years, it has been shown that human leukocyte antigen (HLA) polymorphism has a significant correlation with the incidence of cADRs (9,10). However, other studies have found that some patients with negative HLA polymorphism also suffer from SJS/TEN (11,12).

In this study, the permanent population in Shanghai was taken as the subjects of study to investigate the correlation of HLA-B*15:02 and HLA-A*31:01 polymorphisms with the incidence of cADRs to identify the genetic factors leading to the cADRs.

 Materials and methods <sec> <title>Subjects of study

Child patients treated or admitted to the Department of Neurology, Tianyou Hospital, Tongji University (Shanghai, China) from January, 2015 to January, 2017 were enrolled into the cADRs group (n=30). Child patients enrolled took AEDs for the first time and cADRs occurred within 8 weeks. Patients with other rashes similar to the drug rash were clearly eliminated via the consultation of dermatologists in our hospital. At the same time, 60 child patients treated or admitted to the Department of Neurology, Tianyou Hospital, Tongji University were randomly selected as the AED-tolerant group. This group was administered AEDs for the first time and cADRs did not occur within 8 weeks. Normal children who did not take AEDs were randomly selected as the normal control group. The diagnosis of epileptic children was based on the international general diagnostic criteria (13): i) recurrent convulsion without obvious predisposing causes, and without concurrent infection, hyperpyrexia and other clinical manifestations; ii) EEG examination for child patients indicates an abnormal EEG; iii) all child patients take single AEDs without combined medication. There was no significant difference in the drugs used for child patients between the cADRs and AED-tolerant groups. The child patients and their parents were a permanent Han population in Shanghai.

This experiment was approved by the Ethics Committee of Tianyou Hospital (Shandong, China) and family members of child patients signed the informed consent.

 Materials and instruments

Median whole blood genomic DNA extraction kit (Beijing BioTeke Corp., Beijing, China); HLA-SSO genotyping kit (One Lambda Inc., Canoga Park, CA, USA); ultramicro ultraviolet spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA); PCR amplifier (Applied Biosystems, Foster City, CA, USA); and a flow fluorescence detector (Luminex, Austin, TX, USA) were used in the present study.

 Research methods DNA extraction

DNA was extracted using the median whole blood genomic DNA extraction kit according to the protocol. The purity and concentration of DNA were detected using the Nanodrop-2000 ultramicro ultraviolet spectrophotometer, and the purity and concentration of the DNA samples met the experimental requirements.

 PCR amplification

DNA sample (1 µl) at a concentration of 20–40 ng/µl was taken and added with the substrate, primer and Taq mixture according to the protocol, and vibrated evenly, followed by PCR amplification. The specific reaction parameters are shown in Table I. The amplification products obtained received 2% agarose gel electrophoresis to determine the relevant DNA fragments.

 Sample hybridization

Amplified DNA (5 µl) was taken and added with an appropriate number of magnetic beads and magnetic bead buffer, vibrated evenly and then incubated on the PCR amplification instrument at 60°C for 15 min. The mixture was washed with 50 µl washing liquid 3 times, added with 25 µl fluorescent liquid and incubated at 60°C for 5 min. After being washed again 3 times, the samples were read on Hoefer DQ 200 flow fluorometer (Hoefer, Inc., Piscataway, NJ, USA).

 Statistical methods

SPSS 19.0 software (IBM, Armonk, NY, USA) was used for statistical analysis. Measurement data are presented as mean ± SD, and one-way analysis of variance was used for the comparison among groups. Tukey test was used as post hoc test. HLA gene frequency in each group was calculated using the direct counting method. Chi-square test or Fisher's exact test was used for the comparison of HLA gene frequency in each group. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Comparison of general data

In the cADRs group, there were 9 child patients with SJS, 4 child patients with TEN, 6 child patients with HSS and 11 child patients with MPE. There were no significant differences in sex ratio and age among the three groups of children (Table II).

 Comparison of HLA-B*15:02 gene frequency in each group

The pairwise comparison was made for HLA-B*15:02 gene frequency in child patients in the three groups. The results showed that the positive rate of HLA-B*15:02 gene in the cADRs group was significantly higher than that in the AED-tolerant and normal groups, and the differences were statistically significant [P<0.001, odds ratio (OR)=7.143, 95% confidence interval (CI)=3.496–14.593; P<0.001, OR=25.00, 95% CI=6.34–98.578]. There was no statistically significant difference between AED-tolerant group and normal group (P>0.05) (Tables III–V).

 Comparison of HLA-A*31:01 gene frequency in each group

The pairwise comparison was carried out for the HLA-A*31:01 gene frequency in child patients for the three groups. The results showed that the positive rate of HLA-A*31:01 gene in the cADRs group was significantly higher than that in the AED-tolerant and normal groups, and the differences were statistically significant (P<0.001, OR=2.235, 95% CI=1.375–3.634; P=<0.001, OR=4.222, 95% CI=2.18–8.177). There was no statistically significant difference between the AED-tolerant and normal groups (P>0.05) (Tables VI–VIII).

 Discussion

cADR is the delayed-type hypersensitivity mediated by immune mechanisms, whose incidence is associated with sex, age, region, initial dose of AEDs and history of allergy (8) In addition, its incidence is unpredictable and heterogeneous (14). MPE is the most common AED-induced cADR, and its main clinical manifestations are pink small papules and maculae on skin without involving the mucosa or organs, which can gradually disappear after drug withdrawal (15). The clinical manifestations of HSS, in addition to rash, are accompanied with multi-organ involvement and eosinophilia, while those of SJS and TEN are blister-like rash on skin, involving mucosal and multiple organs, accompanied with systemic excoriation. Excoriation of less than 10% indicates SJS, excoriation of greater than 30% indicates TEN, and excoriation between 10 and 30% indicates SJS/TEN overlap (5). The mortality rate of TEN is as high as 30–50% (16). It has been found that male patients are more likely to suffer from serious cADRs than female patients (17), and cADRs occur more easily in infants and the elderly (18). The incidence rate of cADRs varies from country to country: it is 6.60% in Japan, 5.88% in Australia, 27.70% in Singapore, 19.00% in India, 35.70% in Malaysia and 26.00% in Taiwan (19). It can be seen that the genetic specificity has an important influence on the occurrence of cADRs.

Studies have confirmed that HLA gene is closely related to serious cADRs induced by a variety of drugs. For example, HLA-B*58:01 is a susceptibility gene for serious cADRs caused by allopurinol, and HLA-B*57:01 is a susceptible gene for serious cADRs caused by Abacavir (20). Determining the susceptibility genes of drug-induced cADRs in the clinic can provide a genetic basis for the prevention of cADRs, which is a great progress in drug gene genetics. The HLA gene is located in the 21.31 region of the short arm of human chromosome 6, which has obvious genetic characteristics, and its encoded protein is closely related to the immune rejection after organ transplantation (10). HLA is divided into class I, II and III genes according to the different functions and locations of encoded molecule, of which HLA-A, B and C belong to class I genes (9). In recent years, a large number of studies have confirmed that HLA gene has a significant correlation with AED-induced cADRs, and patients carrying the HLA susceptibility gene are prone to cADRs (9,10).

HLA-B*15:02 locus is studied the most currently. It was found for the first time in 2004 that HLA-B*15:02 is significantly associated with carbamazepine-induced SJS in a Chinese Han population in Taiwan (21). Subsequently, it was confirmed that HLA-B*15:02 is closely associated with carbamazepine-induced SJS/TEN in different ethnic groups in South Asia, such as Thailand, Malaysia, India and Vietnam (22–25). Further studies in Han population found that the correlation of HLA-B*15:02 is related to the degree of skin peeling in SJS/TEN (26). The correlation between HLA-B*15:02 and cADRs has an obvious race specificity, and it is not found in Japanese and European populations. It is speculated that it is related to the very low distribution frequency of HLA-B*15:02 in these populations (7,27). However, the distribution frequencies of HLA-B*15:02 in China, Indian and Philippines are as high as 8, 21 and 34%, respectively (20,25). The present findings have shown that HLA-B*15:02 is a risk factor for carbamazepine-induced cADRs in the Asian population. The present findings have also confirmed that HLA-B*15:02 was strongly associated with AED-induced cADRs in Han population in Shanghai, which was consistent with the study on Han population in other areas of China. Thus, now it is recommended by many regulators that HLA-B*15:02 genotyping be performed before administration of carbamazepine and other AEDs, thereby reducing the incidence of cADRs (22,25,28).

HLA-A*31:01 is another genotype that is closely related to AED-induced cADRs. The distribution frequencies of HLA-A*31:01 in Chinese Han population, Japanese, Korean and Caucasian population are 2.2, 9.3, 5 and 4.2%, respectively. However, its distribution frequency was as low as 0.01% in an African population (29). A number of studies in Japanese and European populations have shown that HLA-A*31:01 is strongly associated with AED-induced cADRs (27,30). Genin et al (31) found in meta-analysis in different ethnic groups that HLA-A*31:01 is significantly associated with the carbamazepine-induced HSS (OR=13.2, 95% CI=8-20.8), indicating that HLA-A*31:01 is a specific susceptibility gene for carbamazepine-induced HSS. Another meta-analysis found that (32) the specificity of HLA-A*31:01 was 0.871–0.972, the sensitivity was 0.262–0.584, the negative predictive value was 0.921–0.986 and the positive predictive value was 0.119–0.427 in the prediction of cADRs via HLA-A*31:01 gene screening in Han population in Japan, Europe and China (32). Therefore, it is recommended by Canada Pharmacogenomics Safety Network that HLA-A*31:01 gene screening be performed for patients before the application of carbamazepine, and carbamazepine be avoided for genetically positive patients (25). The present study also confirmed that HLA-A*31:01 has a significant correlation with the AED-induced cADRs in a Han population in Shanghai, which is consistent with the result in previous cohort studies. Therefore, HLA-A*31:01 gene screening prior to the administration of AEDs plays an important role in the prevention of cADRs.

In conclusion, it was confirmed in the present study that HLA-B*15:02 and HLA-A*31:01 are significantly associated with cADRs in Chinese Han population in Shanghai, and HLA-B*15:02 and HLA-A*31:01 gene screening prior to the administration of AEDs can prevent the occurrence of cADRs. In this study, the sample size was small, and it was a mixed study on a number of AEDs; thus, the sample size should be increased, and the control study on single drug and the interaction research among multiple genes are needed in the future. This study only aimed at a single HLA gene. As such, other relevant risk or protective factors remain to be further studied.

 Acknowledgements

Not applicable.

 Funding

No funding was received.

 Availability data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

 Author's contributions

YH contributed to the conception of the study. JZ contributed significantly to analysis and manuscript preparation. XL performed the data analyses and wrote the manuscript. YS, MS and JW helped perform the analysis with constructive discussions.

 Ethics approval and consent to participate

This experiment was approved by the Ethics Committee of Tianyou Hospital and family members of child patients signed the informed consent.

 Consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References AhmedSNEpileptic seizures and epilepsyEpilepsia4617001702200510.1111/j.1528-1167.2005.00273_3.x16190950 DingDHongZWangWZWuJZde BoerHMPrilipkoLSanderJWAssessing the disease burden due to epilepsy by disability adjusted life year in rural ChinaEpilepsia4720322037200610.1111/j.1528-1167.2006.00802.x17201700 ZaccaraGPeruccaEInteractions between antiepilepticdrugs, and between antiepileptic drugs and other drugsEpileptic Disord16409431201425515681 GreenwoodRSAdverse effects of antiepileptic drugsEpilepsia41Suppl 2S42S52200010.1111/j.1528-1157.2000.tb01523.x10885739 WangXQLangSYShiXBTianHJWangRFYangFAntiepileptic drug-induced skin reactions: A retrospective study and analysis in 3793 Chinese patients with epilepsyClin Neurol Neurosurg114862865201210.1016/j.clineuro.2012.01.01922321756 WangXQShiXBAuRChenFSWangFLangSYInfluence of chemical structure on skin reactions induced by antiepileptic drugs - the role of the aromatic ringEpilepsy Res94213217201110.1016/j.eplepsyres.2011.02.00521377329 LonjouCThomasLBorotNLedgerNde TomaCLeLouetHGrafESchumacherMHovnanianAMockenhauptMRegiSCAR GroupA marker for Stevens-Johnson syndrome & Ethnicity mattersPharmacogenomics J6265268200610.1038/sj.tpj.650035616415921 LujićLBošnjakVMDuranovićVDakovićIKapovićAMBarčotZJurekovićIIIdiosyncratic adverse reactions to aromatic antiepileptic drugsPaediatr Croat571651702013 HungSIChungWHLiuZSChenCHHsihMSHuiRCChuCYChenYTCommon risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han ChinesePharmacogenomics11349356201010.2217/pgs.09.16220235791 CheungYKChengSHChanEJLoSVNgMHKwanPHLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han ChineseEpilepsia5413071314201310.1111/epi.1221723692434 TassaneeyakulWTiamkaoSJantararoungtongTChenPLinSYChenWHKonyoungPKhunarkornsiriUAuvichayapatNPavakulKAssociation between HLA-B'1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai populationEpilepsia51926930201010.1111/j.1528-1167.2010.02533.x20345939 MehtaTYPrajapatiLMMittalBJoshiCGShethJJPatelDBDaveDMGoyalRKAssociation of HLA-B'1502 allele and carbamazepine-induced Stevens-Johnson syndrome among IndiansIndian J Dermatol Venereol Leprol75579582200910.4103/0378-6323.5771819915237 HungSIChungWHJeeSHChenWCChangYTLeeWRHuSLWuMTChenGSWongTWGenetic susceptibility to carbamazepine-induced cutaneous adverse drug reactionsPharmacogenet Genomics16297306200610.1097/01.fpc.0000199500.46842.4a16538176 GogtayNJBavdekarSBKshirsagarNAAnticonvulsant hypersensitivity syndrome: A reviewExpert Opin Drug Saf4571581200510.1517/14740338.4.3.57115934861 ArifHBuchsbaumRWeintraubDKoyfmanSSalas-HumaraCBazilCWResorSRJrHirschLJComparison and predictors of rash associated with 15 antiepileptic drugsNeurology6817011709200710.1212/01.wnl.0000261917.83337.db17502552 AboodGJNickoloffBJGamelliRLTreatment strategies in toxic epidermal necrolysis syndrome: Where are we at?J Burn Care Res29269276200810.1097/BCR.0b013e31815f365818182932 LammintaustaKKortekangas-SavolainenOThe usefulness of skin tests to prove drug hypersensitivityBr J Dermatol152968974200510.1111/j.1365-2133.2005.06429.x15888154 MessenheimerJAGubermanAHRash with lamotrigine: Dosing guidelinesEpilepsia41488200010.1111/j.1528-1157.2000.tb00197.x10756418 ChungWHHungSIChenYTGenetic predisposition of life-threatening antiepileptic-induced skin reactionsExpert Opin Drug Saf91521201010.1517/1474033090342796920001755 ChungWHHungSIRecent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosisJ Dermatol Sci66190196201210.1016/j.jdermsci.2012.04.00222541332 ChungWHHungSIHongHSHsihMSYangLCHoHCWuJYChenYTMedical genetics: A marker for Stevens-Johnson syndromeNature428486200410.1038/428486a15057820 ChengCYSuSCChenCHChenWLDengSTChungWHHLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: An updated reviewJ Immunol Res2014565320201410.1155/2014/56532024901010 NguyenDVChuHCNguyenDVPhanMHCraigTBaumgartKvan NunenSHLA-B'1502 and carbamazepine-induced severe cutaneous adverse drug reactions in VietnameseAsia Pac Allergy56877201510.5415/apallergy.2015.5.2.6825938071 TangamornsuksanWChaiyakunaprukNSomkruaRLohitnavyMTassaneeyakulWRelationship between the HLA-B'1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysisJAMA Dermatol14910251032201310.1001/jamadermatol.2013.411423884208 AmstutzUShearNHRiederMJHwangSFungVNakamuraHConnollyMBItoSCarletonBCCPNDS clinical recommendation groupRecommendations for HLA-B'15:02 and HLA-A'31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactionsEpilepsia55496506201410.1111/epi.1256424597466 HsiaoYHHuiRCWuTChangWCHsihMSYangCHHoHCChangYGChenMJLinJYGenotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: Strength and clinical correlationsJ Dermatol Sci73101109201410.1016/j.jdermsci.2013.10.00324268988 OzekiTMushirodaTYowangATakahashiAKuboMShirakataYIkezawaZIijimaMShioharaTHashimotoKGenome-wide association study identifies HLA-A'3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese populationHum Mol Genet2010341041201110.1093/hmg/ddq53721149285 LeckbandSGKelsoeJRDunnenbergerHMGeorgeALJrTranEBergerRMüllerDJWhirl-CarrilloMCaudleKEPirmohamedMClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosingClin Pharmacol Ther94324328201310.1038/clpt.2013.10323695185 KuroseKSugiyamaESaitoYPopulation differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: Implications in the clinical trials for novel drug developmentDrug Metab Pharmacokinet27954201210.2133/dmpk.DMPK-11-RV-11122123129 McCormackMAlfirevicABourgeoisSFarrellJJKasperavičiūtėDCarringtonMSillsGJMarsonTJiaXde BakkerPIHLA-A'3101 and carbamazepine-induced hypersensitivity reactions in EuropeansN Engl J Med36411341143201110.1056/NEJMoa101329721428769 GeninEChenDPHungSISekulaPSchumacherMChangPYTsaiSHWuTLBellónTTamouzaRHLA-A'31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysisPharmacogenomics J14281288201410.1038/tpj.2013.4024322785 YipVLMarsonAGJorgensenALPirmohamedMAlfirevicAHLA genotype and carbamazepine-induced cutaneous adverse drug reactions: A systematic reviewClin Pharmacol Ther92757765201210.1038/clpt.2012.18923132554

PCR reaction parameters.

Step Temperature (°C) Time Cycle
1 96 3 min   1
2 96 20 sec   5
60 20 sec
72 20 sec
3 96 10 sec 30
60 15 sec
72 20 sec
4 72 10 min   1

Comparison of general data.

Group n Male/female (n) Age (years)
cADR 30 22/8 10.26±2.33
AED-tolerant 60 42/18 9.72±2.81
Normal 60 45/15 10.95±2.54

Comparison of HLA-B*15:02 gene frequency between the cARD and AED-tolerant groups.

Group Positive Negative Gene frequency (%) χ2 test P-value
cARD 25   5 83.33 46.886 <0.001
AED-tolerant   7 53 11.67

Comparison of HLA-B*15:02 gene frequency between the cARD and normal groups.

Group Positive Negative Gene frequency (%) χ2 test P-value
cARD 25   5 83.33 65.385 <0.001
Normal   2 58   3.33

Comparison of HLA-B*15:02 gene frequency between the AED-tolerant and normal groups.

Group Positive Negative Gene frequency (%) χ2 test P-value
AED-tolerant 7 53 11.67 3.003 0.083
Normal 2 58   3.33

Comparison of HLA-A*31:01 gene frequency between the cARD and AED-tolerant groups.

Group Positive Negative Gene frequency (%) χ2 test P-value
cARD 19 11 63.33 10.184 0.001
AED-tolerant 17 43 28.33

Comparison of HLA-A*31:01 gene frequency between the cARD and normal groups.

Group Positive Negative Gene frequency (%) χ2 test P-value
cARD 19 11 63.33 21.223 <0.001
Normal   9 51 15.00

Comparison of HLA-A*31:01 gene frequency between the AED-tolerant and normal groups.

Group Positive Negative Gene frequency (%) χ2 test P-value
AED-tolerant 17 43 28.33 3.184 0.074
Normal   9 51 15.00